Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
Bio Pharma Dive
APRIL 22, 2024
billion, is the latest research collaboration involving small molecule drugs that modify RNA. The deal, which could be worth up to $1.8
Bio Pharma Dive
APRIL 22, 2024
billion, is the latest research collaboration involving small molecule drugs that modify RNA. The deal, which could be worth up to $1.8
Pharmaceutical Technology
APRIL 22, 2024
Discover how Silence Therapeutics' patented compound for RNA interference therapy targets liver disease with precision. Learn about the specific chemical formula and potential therapeutic benefits outlined in the recently granted patent.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioSpace
APRIL 21, 2024
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
pharmaphorum
APRIL 22, 2024
bn alliance with Skyhawk Therapeutics focused on RNA-modulating drugs for rare neurological diseases. Ipsen agrees $1.8
Pharmaceutical Technology
SEPTEMBER 9, 2022
US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). Gatehouse Bio is engaged in developing small RNA-based therapeutics using AI technology.
Pharmaceutical Technology
AUGUST 3, 2023
AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.
Pharmaceutical Technology
MAY 23, 2023
ReNAgade Therapeutics has burst onto the RNA technology scene by announcing a $300m financing round. With its delivery system, Cambridge, Massachusetts-based biotech says it aims to “address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body.”
Let's personalize your content